Exelixis, Inc. (EXEL) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended July 3, 2026 (referred to as June 30, 2026, for convenience). Exelixis is an oncology company focused on the discovery, development, and commercialization of medicines for difficult-to-treat cancers. The company's revenue is primarily driven by its flagship molecule, cabozantinib (marketed as CABOMETYX and COMETRIQ), and collaboration agreements with partners such as Ipsen and Takeda. The company is also advancing its lead clinical asset, zanzalintinib, which is under FDA review for colorectal cancer.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Total Revenues | $628,690 | $568,261 | $1,239,502 | $1,123,708 |
| Net Product Revenues | $573,025 | $520,014 | $1,128,002 | $1,033,297 |
| Collaboration Revenues | $55,665 | $48,247 | $111,500 | $90,411 |
| Net Income | $212,050 | $184,848 | $422,517 | $344,464 |
| Diluted EPS | $0.82 | $0.65 | $1.60 | $1.20 |
| Operating Cash Flow (6mo) | $559,586 | $260,430 | - | - |
| Cash & Marketable Securities | $1,384,315 | - | - | - |
| Working Capital | $888,895 | - | - | - |
Note: Cash and Marketable Securities as of June 30, 2026, was $1.38 billion, down from $1.66 billion at year-end 2025. Gross margin remained stable at 96%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 11% in Q2 2026 compared to Q2 2025. Net product revenues grew 10%, driven by a 6% increase in CABOMETYX unit sales and a 4% increase in average net selling price. Collaboration revenues rose 15%, largely due to higher royalties from Ipsen and a $7.8 million commercial milestone from Takeda.
- Profitability: Net income increased 15% to $212.1 million in Q2 2026. The effective tax rate was 19.3% for the quarter.
- Expenses: Research and development (R&D) expenses increased 6% to $212.0 million, primarily due to higher clinical trial costs for zanzalintinib and biotherapeutics. Selling, general, and administrative (SG&A) expenses rose 9% to $147.6 million, driven by marketing activities for zanzalintinib pre-launch.
- Capital Allocation: The company completed its October 2025 stock repurchase program ($750 million) and initiated a new $750 million program in May 2026. As of June 30, 2026, the company had repurchased 20.2 million shares for $902.2 million, with approximately $597.8 million remaining available under the new program.
Guidance, Outlook, and Risks
- Pipeline Progress: The FDA accepted the New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer, with a PDUFA target action date of December 3, 2026. Positive top-line results were announced for the STELLAR-303 trial showing a statistically significant improvement in overall survival.
- Outlook: Management projects net product revenues may increase for the remainder of 2026. R&D and SG&A expenses are expected to increase due to ongoing clinical trials and pre-launch marketing for zanzalintinib.
- Legal Proceedings: The company is engaged in multiple patent litigations regarding generic versions of CABOMETYX (MSN, Azurity, Handa, Accord, Almatica). A consolidated trial is scheduled for November 2, 2026. The outcome of these proceedings could materially impact future revenues if generic competition enters the market earlier than expected.
- Regulatory Risks: The company faces potential pricing pressures from the Inflation Reduction Act (IRA) and proposed "Most Favored Nation" pricing policies, though it currently qualifies for the "small biotech" exception through 2028.
Key Facts for Investor Verification
- Zanzalintinib NDA Status: Verify the FDA's final decision timeline and any potential Complete Response Letters regarding the December 2026 PDUFA date.
- Patent Litigation Outcomes: Monitor the November 2026 consolidated trial results involving MSN, Azurity, and other generic applicants, as a loss could significantly reduce CABOMETYX revenue projections.
- Stock Repurchase Activity: Track the utilization of the remaining $597.8 million authorization under the May 2026 SRP and its impact on share count and EPS.
- Collaboration Milestones: Confirm future milestone triggers with Ipsen and Takeda, which contribute significantly to non-product revenue volatility.
- IRA Pricing Impact: Assess the long-term impact of the "small biotech" exception expiration in 2028 on the pricing power of the cabozantinib franchise.